Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus, with revenue of $39.7M exceeding expectations by 17.1% and GAAP EPS of $0.14 surpassing the $0.11 mean estimate. Performance was driven by robust MIPLYFFA adoption ($30.2M sales) and a stabilized market access of 69%. Adjusted net income reached $15.2M, reflecting strong operating leverage as SG&A expenses fell 20% YoY, while the cash position remains solid at $260.2M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Zevra Therapeutics(ZVRA) the Revenue is 39.66 M (+53.25%), Beat estimate;the EBIT is 16.78 M (+123.6%), Beat estimate;the EPS is 0.14 (-88.43%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.04B53.25%
0.03B30.92%
+0.01B22.33%
EBITExceed expectations
0.02B123.62%
0.01B109.52%
+0.01B14.10%
EPSExceed expectations
0.1488.43%
0.108991.00%
+0.03112.57%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf